Razvitie BioTechnologiy

Razvitie BioTechnologiy is a Russian biotechnology company primarily focused on the development of next-generation vaccines using nanoparticle technology. The company's flagship product is Betuvax-CoV-2, a recombinant subunit vaccine against COVID-19 that utilizes betulin-based nanoparticles as an adjuvant and delivery system. It operates as a project company within the Artgen Biopharma (formerly Human Stem Cells Institute) group. The company's technology platform is designed to create safe and effective vaccines for various infectious diseases by mimicking viral particles. Razvitie BioTechnologiy emphasizes a high safety profile, making its products suitable for revaccination and use in vulnerable populations. The company successfully navigated the clinical trial process in Russia, leading to the registration of its lead candidate.